5324882025-07-012025-09-305324882025-09-305324882025-03-315324882025-04-012025-09-305324882025-07-012025-09-30in-capmkt:OtherExpenses1Member5324882025-04-012025-09-30in-capmkt:OtherExpenses1Member5324882025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15324882025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15324882025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15324882025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15324882025-07-012025-09-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532488DIVISLABNOTLISTEDINE361B01024Divi's Laboratories LimitedMain BoardEquity2025-04-012026-03-312025-11-072025-10-27INRCroresQuarterlySecond quarterSingle segmentManufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients2025-11-0710:30:002025-11-0711:45:00trueCash Flow IndirectDeclaration of unmodified opinion2025-07-012025-09-30UnauditedConsolidated271500000001450000000286000000009370000000013600000003540000000800000001130000000400000000019480000000912000000009120000000220000000030000000223000000006890000000000068900000003000000069200000006890000000069200000000530000000225.9725.970025.9725.971. The above Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2025, Statement of Consolidated Unaudited Assets and Liabilities as at 30th September, 2025 and Statement of Consolidated Unaudited Cash Flows for the half year ended 30th September, 2025 (Consolidated Statements) are prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This Consolidated Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 07, 2025. The statutory auditors have carried out a limited review of this Consolidated Statements and issued an unmodified report thereon. <BR> 2. The Consolidated Unaudited Financial Results include the financial results of Divis Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divis Laboratories Europe AG (Referred as the Group) <BR> 3. The Group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108. <BR> 4. The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only. <BR> 5. Details of Forex gain are as given below: <BR> (Rs. in Crores) <BR> Quarter ended Half Year ended Year ended <BR> 30.09.2025 30.06.2025 30.09.2024 30.09.2025 30.09.2024 31.03.2025 <BR> Forex gain 63 39 29 102 28 48 <BR> Forex gain has been included in other income. <BR> <BR> 2025-04-012025-09-30UnauditedConsolidated5125000000026400000005389000000019470000000082000000069400000001100000002250000000785000000037440000000164500000000164500000004110000000041100000000123400000000000123400000006000000012400000000123400000000124000000000530000000246.4646.460046.4646.46Other expenses4000000000Other expenses7850000000567200000002030000000004000000067000000006500000001320000000120000000458000000083080000000343300000000261400000008300000003178000000008000000058830000000527000000098430000000001815100000005300000001536000000001541300000000154130000000027400000002740000000051200000002240000000101000000008900000009000000010310000000104000000002680000000139700000002240000000620000000450000000172800000002738000000018151000000050000000-197000000018800000000-14300000000-3000000080000000012400000000-1330000000224000000022500000000100000000700000002600000000-400000000015700000000-20000000000003670000000201200000000003670000000016450000000000000003000000015440000000000000000000000000158000000001220000000-126100000000000000000200000007960000000500000000830000000-7200000000-33600000000-33600000004130000000770000000Gain/(loss) on Remeasurement of post-employment benefit obligations00Gain/(loss) on Remeasurement of post-employment benefit obligations-10000000-1000000000Gain on exchange differences in translating the financial statements of foreign operations5000000050000000Gain on exchange differences in translating the financial statements of foreign operations900000009000000020000000200000003000000060000000UnauditedtruePrice Waterhouse Chartered Accountants LLPtrue2026-11-30